Global Dactylitis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Dactylitis Treatment Market Overview

The global Dactylitis Treatment market was valued at USD 10.91 billion in 2025 and is projected to reach USD 21.73 billion by 2033, growing at a CAGR of 9.00% from 2026 to 2033. The market is experiencing consistent growth driven by rising demand for safe and realistic driver training solutions, rapid advancements in simulation hardware and software, and expanding applications across automotive R&D, defense, and professional motorsport.

The increasing incidence of road accidents globally, combined with stricter government regulations on driver training and road safety, is compelling transportation authorities, driving schools, and military organizations to adopt advanced simulation technologies. Fixed-base and VR/AR-enabled simulators are replacing traditional on-road training in many markets, offering cost-effective, repeatable, and risk-free environments for skill development and autonomous vehicle validation.

Key Market Trends & Insights

• North America dominated the global Dactylitis Treatment market with the largest revenue share of 35.88% in 2025, supported by advanced healthcare infrastructure, increasing adoption of biologic therapies, and rising prevalence of psoriatic arthritis and inflammatory disorders.
• The Disease-Modifying Antirheumatic Drugs (DMARDs) segment led the market with a 40.92% share in 2025, driven by its effectiveness in reducing inflammation, slowing disease progression, and improving long-term patient outcomes.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.3% from 2026 to 2033, fueled by improving healthcare access, rising awareness regarding autoimmune disorders, and expanding diagnostic capabilities across China, India, and Japan.
• The Imaging Tests segment is the fastest-growing diagnosis type, projected to register a CAGR of 7.0%, reflecting increasing demand for accurate assessment of joint inflammation and disease progression.
• The Swelling segment dominates the symptoms category with a 38.64% revenue share in 2025, led by its high prevalence as the primary clinical manifestation associated with dactylitis and inflammatory joint disorders.
• Oral route of administration accounts for 58.27% of the market, preferred for its ease of administration, improved patient compliance, and widespread use of oral anti-inflammatory and DMARD therapies.
• The Online Pharmacy segment is the fastest-growing distribution channel category, with a CAGR of 6.9%, driven by increasing digital healthcare adoption, expanding e-pharmacy access, and rising preference for convenient medication purchasing platforms.
• The Injection segment dominated the market with a share of 58.42% in 2025 due to the widespread clinical use of injectable biologics, corticosteroids, and anti-inflammatory therapies for rapid symptom relief and effective inflammation management.

Market Size & Forecast

• Global Market Value (2025): USD 10.91 Billion
• Expected Market Value (2033): USD 21.73 Billion
• Forecast CAGR (2026–2033): 9.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Global Dactylitis Treatment Market Segmentation

Global Dactylitis Treatment Market Trends

Trend: Rising Adoption of Biologic Therapies for Inflammatory Disorders

Healthcare providers are increasingly adopting biologic therapies and targeted immunomodulators for the treatment of dactylitis associated with psoriatic arthritis, rheumatoid arthritis, and sickle cell disease. Advanced biologic drugs such as TNF inhibitors and interleukin inhibitors are improving long-term inflammation control, reducing joint damage, and enhancing patient quality of life. Hospitals and specialty rheumatology clinics are also leveraging advanced diagnostic imaging and personalized treatment approaches to improve disease monitoring and therapy optimization. In addition, increasing awareness regarding early intervention and chronic inflammatory disease management is accelerating the adoption of precision-based therapies across developed healthcare markets.

Global Dactylitis Treatment Market Dynamics

Key Market Driver: Increasing Prevalence of Autoimmune and Inflammatory Disorders

The rising prevalence of autoimmune diseases such as psoriatic arthritis and rheumatoid arthritis has created substantial demand for advanced dactylitis treatment solutions globally. According to the World Health Organization (WHO), musculoskeletal disorders affect nearly 1.71 billion people worldwide, significantly increasing the burden of inflammatory joint conditions and associated complications. Pharmaceutical companies and healthcare providers are increasingly investing in biologic therapies, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) to improve patient outcomes and reduce disease progression. In addition, growing awareness regarding early diagnosis and increasing adoption of advanced imaging technologies such as MRI and ultrasound are accelerating treatment accessibility across hospitals and specialty clinics globally.

Key Restraint/Challenge: High Cost of Biologic Therapies and Limited Specialist Access

A significant restraint in the global Dactylitis Treatment market is the high treatment cost associated with biologic drugs, long-term immunotherapy, and advanced diagnostic procedures. Modern biologic therapies including TNF inhibitors and interleukin blockers require continuous administration, specialist supervision, and regular monitoring, increasing overall healthcare expenditure for patients and healthcare systems. For instance, annual treatment costs for biologic therapies used in psoriatic arthritis management can exceed USD 20,000 per patient in several developed healthcare markets depending on dosage frequency and insurance coverage. In many low- and middle-income countries, limited access to rheumatologists, delayed diagnosis, and inadequate reimbursement support continue to restrict treatment adoption. The growing burden of healthcare inequality and limited availability of advanced therapies in emerging healthcare systems further challenge broader market penetration globally.

Key Market Opportunity: Expansion of Precision Medicine and Advanced Diagnostic Technologies

The growing focus on personalized medicine and targeted inflammatory disease management presents a significant market opportunity for the Dactylitis Treatment market. Advances in genomic research, biomarker-based diagnostics, and AI-assisted imaging technologies are supporting the development of more accurate and individualized treatment strategies. For instance, increasing adoption of MRI and ultrasound imaging for early inflammatory joint detection across the U.S., Germany, and Japan is improving disease diagnosis and treatment planning outcomes. In addition, collaborations between pharmaceutical companies and research organizations for biologic drug development are accelerating innovation in autoimmune disease therapeutics. Expanding healthcare infrastructure, rising investment in specialty rheumatology care, and improving access to advanced therapies across Asia-Pacific and Latin America are also creating substantial growth opportunities for treatment providers and pharmaceutical manufacturers globally.

Global Dactylitis Treatment Market Scope

The Dactylitis Treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel.

By Treatment

On the basis of treatment, the global Dactylitis Treatment market is segmented into antibiotics, disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid, and others. The Disease-Modifying Antirheumatic Drugs (DMARDs) segment dominated the market with a 40.92% share in 2025 due to its strong effectiveness in controlling inflammation, slowing disease progression, and improving long-term joint function in patients with psoriatic arthritis and other inflammatory disorders associated with dactylitis. High adoption is supported by increasing physician preference for targeted immunomodulatory therapies and rising clinical evidence supporting early intervention with DMARD treatment protocols. In addition, growing prevalence of autoimmune diseases, expanding biologic DMARD availability, and increasing reimbursement support across developed healthcare systems are strengthening segment dominance globally. Pharmaceutical companies are also increasing investment in advanced biologic and biosimilar DMARD therapies to improve treatment accessibility and long-term disease management outcomes. The widespread use of DMARDs across hospitals, rheumatology clinics, and specialty care centers continues to reinforce their leading position in the market. Rising awareness regarding chronic inflammatory disease management and advancements in precision medicine are further contributing to strong segment growth worldwide.

The Corticosteroid segment is expected to witness the fastest CAGR of 7.2% from 2026 to 2033, driven by increasing adoption for rapid inflammation control and pain management in acute dactylitis cases. Growth is further supported by rising utilization of injectable corticosteroid therapies across hospitals and specialty rheumatology clinics for immediate symptomatic relief. Healthcare providers are increasingly recommending corticosteroids for patients experiencing severe swelling, tenderness, and reduced joint mobility associated with inflammatory disorders. In addition, advancements in localized corticosteroid injection techniques and improved treatment protocols are enhancing therapeutic effectiveness and patient outcomes. Increasing awareness regarding early intervention strategies and expanding healthcare access in emerging economies are also accelerating segment demand. Pharmaceutical manufacturers are focusing on the development of safer corticosteroid formulations with reduced long-term adverse effects, further supporting market expansion. Rising incidence of autoimmune and musculoskeletal disorders globally is contributing to greater treatment adoption across both developed and developing healthcare markets. Furthermore, growing investment in rheumatology care infrastructure and increasing availability of specialist services are positively influencing the rapid growth of the corticosteroid segment worldwide.

By Diagnosis

On the basis of diagnosis, the global Dactylitis Treatment market is segmented into blood tests, imaging tests, laboratory tests, and others. The Blood Tests segment dominated the market with a share of 39.68% in 2025 due to its widespread use in identifying inflammatory markers, infection levels, and autoimmune activity associated with dactylitis and related musculoskeletal disorders. High adoption is supported by cost-effectiveness, rapid turnaround time, and increasing implementation across hospitals, diagnostic laboratories, and specialty rheumatology centers globally. Blood tests play a critical role in evaluating disease severity, monitoring treatment response, and differentiating inflammatory conditions from infectious disorders. In addition, increasing prevalence of autoimmune diseases and rising awareness regarding early diagnosis are strengthening demand for routine hematological and inflammatory marker testing. Healthcare providers continue to rely heavily on blood-based diagnostics for comprehensive patient assessment and long-term disease monitoring. Expanding laboratory infrastructure and advancements in biomarker detection technologies are further reinforcing the dominance of this segment across developed and emerging healthcare markets.

The Imaging Tests segment is expected to witness the fastest CAGR of 7.0% from 2026 to 2033, driven by increasing adoption of MRI, ultrasound, and advanced radiographic imaging technologies for accurate assessment of joint inflammation and tissue damage. Growth is further supported by rising demand for early-stage diagnosis and precision-based treatment planning in inflammatory musculoskeletal disorders. Healthcare providers are increasingly integrating imaging technologies into rheumatology diagnostic workflows to improve disease monitoring and therapeutic decision-making. In addition, advancements in high-resolution imaging systems and AI-assisted radiology platforms are enhancing diagnostic accuracy and clinical efficiency. Expanding healthcare infrastructure and growing access to specialty diagnostic centers across emerging markets are also accelerating segment growth. Increasing awareness regarding the benefits of early inflammatory disease detection and improved patient outcomes is contributing to greater imaging test adoption globally. Furthermore, rising investment in digital healthcare technologies and precision medicine initiatives is strengthening long-term market expansion for advanced diagnostic imaging solutions.

By Symptoms

On the basis of symptoms, the global Dactylitis Treatment market is segmented into swelling, fever, pain, warmth, tenderness, tightness, mild anemia, reduced function, increased white blood cell count, and others. The Swelling segment dominated the market with a share of 38.64% in 2025 due to its high prevalence as the most common and clinically recognizable symptom associated with dactylitis and inflammatory joint disorders. Increasing patient admissions related to severe finger and toe swelling are supporting strong treatment demand globally. Physicians and rheumatology specialists prioritize swelling assessment for early diagnosis, disease monitoring, and treatment planning, contributing to higher adoption of anti-inflammatory therapies and biologic drugs. In addition, rising prevalence of psoriatic arthritis, sickle cell disease, and autoimmune musculoskeletal disorders is reinforcing the dominance of this segment. Healthcare providers are increasingly utilizing imaging and laboratory diagnostics to evaluate swelling severity and inflammatory progression in affected patients. Growing awareness regarding chronic inflammatory diseases and improved access to specialty rheumatology care are further supporting segment growth worldwide.

The Reduced Function segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by increasing focus on restoring mobility, improving quality of life, and preventing long-term disability among patients with inflammatory joint disorders. Growth is further supported by rising adoption of rehabilitation therapies, biologic treatments, and advanced pain management solutions aimed at improving physical functionality. Healthcare providers are increasingly emphasizing early therapeutic intervention to reduce joint stiffness, mobility limitations, and work-related disability associated with dactylitis. In addition, growing awareness regarding functional impairment assessment and patient-centered treatment approaches is accelerating segment expansion. Advancements in physical therapy techniques, personalized rehabilitation programs, and supportive orthopedic care are further contributing to market growth. Increasing prevalence of chronic autoimmune diseases and aging population demographics are also strengthening long-term demand for therapies focused on improving joint functionality. Furthermore, expanding healthcare access and rising investment in musculoskeletal disease management programs are positively influencing segment development globally.

By Dosage

On the basis of dosage, the global Dactylitis Treatment market is segmented into injection, tablets, and others. The Injection segment dominated the market with a share of 58.42% in 2025 due to the widespread clinical use of injectable biologics, corticosteroids, and anti-inflammatory therapies for rapid symptom relief and effective inflammation management. High adoption is supported by increasing physician preference for injectable treatments in moderate-to-severe dactylitis cases requiring immediate therapeutic response. In addition, rising availability of advanced biologic injections, expanding hospital-based treatment programs, and growing long-term disease management initiatives are reinforcing segment dominance globally. Pharmaceutical companies are increasingly investing in injectable immunotherapy and biosimilar development to improve patient outcomes and treatment accessibility. The growing prevalence of autoimmune and inflammatory musculoskeletal disorders is further accelerating demand for injectable therapies across hospitals and specialty rheumatology clinics worldwide.

The Tablets segment is expected to witness the fastest CAGR of 6.7% from 2026 to 2033, driven by increasing demand for convenient oral therapies, improved patient compliance, and growing preference for home-based treatment approaches. Growth is further supported by expanding availability of oral NSAIDs, DMARDs, and supportive anti-inflammatory medications across retail and online pharmacy channels globally. Pharmaceutical companies are focusing on the development of advanced oral formulations that improve therapeutic effectiveness and long-term disease control. In addition, rising awareness regarding chronic disease management and patient-centric healthcare approaches is accelerating adoption of tablet-based therapies. Expanding healthcare infrastructure and improving medication accessibility across emerging economies are also contributing to strong segment growth. Increasing geriatric population and growing prevalence of autoimmune inflammatory disorders are further strengthening demand for oral treatment solutions worldwide. Furthermore, advancements in oral drug delivery systems and supportive reimbursement policies are positively influencing long-term market expansion.

By Route of Administration

On the basis of route of administration, the global Dactylitis Treatment market is segmented into oral, intravenous, and others. The Oral segment dominated the market with a share of 56.84% in 2025 due to its widespread use for administering NSAIDs, DMARDs, and corticosteroid therapies in long-term inflammatory disease management. High adoption is supported by ease of administration, improved patient compliance, and increasing preference for home-based treatment approaches across developed and emerging healthcare markets. In addition, expanding availability of oral anti-inflammatory drugs and supportive reimbursement coverage are reinforcing segment dominance globally. Physicians continue to recommend oral therapies for mild-to-moderate dactylitis management due to treatment convenience and lower administration costs. Growing awareness regarding chronic autoimmune disease management and increasing patient adherence to oral medications are further contributing to strong market demand. Pharmaceutical companies are also investing in advanced oral formulations with improved bioavailability and therapeutic effectiveness to strengthen treatment outcomes.
The Intravenous segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by increasing adoption of intravenous biologic therapies and injectable corticosteroids for severe inflammatory conditions requiring rapid therapeutic intervention. Growth is further supported by rising hospitalization rates associated with psoriatic arthritis and autoimmune musculoskeletal complications globally. Healthcare providers are increasingly utilizing intravenous administration for targeted immunotherapy and advanced pain management solutions across specialty rheumatology centers. In addition, advancements in infusion therapy infrastructure and increasing availability of biologic treatment options are accelerating segment growth. Rising investments in hospital-based inflammatory disease management programs and expanding access to specialty care services are also supporting higher intravenous therapy adoption. Furthermore, increasing physician preference for controlled clinical administration and rapid symptom relief in severe dactylitis cases is strengthening long-term market expansion globally.

By End-Users

On the basis of end-users, the global Dactylitis Treatment market is segmented into clinic, hospital, and others. The Hospital segment dominated the market with a share of 47.82% in 2025 due to the high availability of advanced rheumatology care infrastructure, biologic therapy administration facilities, and specialized healthcare professionals. Hospitals remain the primary treatment centers for patients requiring intensive inflammatory disease management, advanced imaging diagnostics, and intravenous immunotherapy. Increasing patient admissions related to psoriatic arthritis, sickle cell disease complications, and severe autoimmune disorders are further supporting segment growth globally. In addition, rising healthcare investments, expanding specialty departments, and increasing adoption of biologic therapies are reinforcing the dominance of hospital-based treatment settings. Strong reimbursement support and multidisciplinary care approaches are also contributing to increased patient preference for hospital treatment services worldwide. Healthcare providers continue to expand rheumatology and musculoskeletal care programs to improve disease diagnosis, treatment accessibility, and long-term patient outcomes.
The Clinic segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by increasing availability of outpatient rheumatology services, growing patient preference for cost-effective treatment settings, and expanding specialty clinic networks globally. Growth is further supported by rising adoption of early-stage diagnosis and long-term disease monitoring services across independent clinics and specialty inflammatory disease centers. Healthcare providers are increasingly establishing dedicated rheumatology clinics to reduce hospital burden and improve treatment accessibility for chronic inflammatory conditions. In addition, shorter waiting periods, personalized care services, and lower treatment costs are accelerating patient preference for clinic-based management approaches. Expanding healthcare infrastructure and increasing investment in outpatient specialty care across emerging markets are also strengthening segment growth. Technological advancements in diagnostic imaging and laboratory testing are further improving treatment efficiency and clinical outcomes in clinic settings. Furthermore, increasing awareness regarding preventive healthcare and early inflammatory disease management is positively influencing long-term demand for clinic-based dactylitis treatment services worldwide.

By Distribution Channel

On the basis of distribution channel, the global Dactylitis Treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The Hospital Pharmacy segment dominated the market with a share of 54.36% in 2025 due to strong in-hospital dispensing of biologic drugs, injectable corticosteroids, and advanced anti-inflammatory therapies used in dactylitis management. High adoption is supported by increasing patient admissions for autoimmune and musculoskeletal disorders requiring specialist supervision and long-term disease monitoring. In addition, hospitals maintain advanced storage infrastructure and regulatory compliance systems necessary for handling temperature-sensitive biologic therapies and injectable medications. Rising demand for integrated patient management and coordinated treatment delivery is further reinforcing the leading position of hospital pharmacies globally. Healthcare providers continue to rely heavily on hospital pharmacy networks for secure access to specialty therapeutics and optimized medication management programs.
The Online Pharmacy segment is expected to witness the fastest CAGR of 7.1% from 2026 to 2033, driven by growing digital healthcare adoption, increasing internet penetration, and rising preference for convenient medication purchasing platforms. Growth is further supported by expanding access to chronic disease medications and supportive therapies through e-pharmacy networks across developed and emerging healthcare markets. Patients are increasingly utilizing online pharmacies due to doorstep delivery services, competitive pricing, and improved medication availability. In addition, integration of e-prescriptions, telemedicine platforms, and digital payment systems is improving accessibility and operational efficiency across online pharmaceutical distribution channels. Pharmaceutical companies and healthcare providers are also strengthening partnerships with digital healthcare platforms to improve patient reach and long-term therapy adherence. Increasing awareness regarding chronic inflammatory disease management and home-based treatment approaches is further contributing to segment growth. Furthermore, supportive regulatory developments and rapid expansion of healthcare e-commerce infrastructure are accelerating online pharmacy adoption worldwide.

Global Dactylitis Treatment Market Regional Analysis

North America dominated the Dactylitis Treatment market and accounted for the largest revenue share of 35.88% in 2025, supported by advanced healthcare infrastructure, increasing adoption of biologic therapies, and rising prevalence of psoriatic arthritis and inflammatory disorders. The region also benefits from strong reimbursement coverage, growing availability of specialty rheumatology care, and increasing use of advanced diagnostic technologies for inflammatory disease management. Rising investments in autoimmune disease research and expanding access to targeted therapies continue to strengthen North America’s leadership position in the global market.

U.S. Dactylitis Treatment Market Insight

The U.S. Dactylitis Treatment market is witnessing strong growth due to rising prevalence of psoriatic arthritis, increasing adoption of biologic drugs, and growing awareness regarding autoimmune inflammatory disorders. The country’s advanced healthcare ecosystem, along with strong presence of leading pharmaceutical companies and rheumatology specialists, is driving demand for targeted treatment solutions across hospital and specialty clinic settings. In addition, growing investments in precision medicine, early diagnosis programs, and advanced immunotherapy research are accelerating market expansion across the U.S.

Europe Dactylitis Treatment Market Insight

The Europe Dactylitis Treatment market remains a major contributor to global revenue, driven by strong healthcare systems, favorable reimbursement frameworks, and increasing focus on autoimmune disease management. The widespread adoption of biologic therapies, DMARDs, and advanced diagnostic technologies across rheumatology centers is supporting market growth throughout the region. Increasing investments in inflammatory disease research, combined with growing patient awareness and access to specialty care services, continue to enhance the adoption of Dactylitis Treatment across Europe.

U.K. Dactylitis Treatment Market Insight

The U.K. Dactylitis Treatment market is experiencing steady growth, supported by increasing prevalence of inflammatory arthritis conditions and rising demand for advanced biologic therapies. Growing investments in rheumatology care infrastructure and expanding access to early diagnostic services are contributing to market development. Furthermore, increasing adoption of targeted immunotherapies, improved patient management programs, and ongoing clinical research initiatives are strengthening the U.K.’s position in the Dactylitis Treatment market.

Germany Dactylitis Treatment Market Insight

The Germany Dactylitis Treatment market is expanding steadily due to the country’s advanced healthcare infrastructure, strong pharmaceutical industry presence, and increasing focus on autoimmune disease treatment innovation. Hospitals, specialty clinics, and rheumatology centers are increasingly adopting biologic therapies and advanced imaging technologies for effective inflammatory disease management. Continuous advancements in personalized medicine, growing healthcare expenditure, and strong government support for chronic disease management programs are further driving market growth in Germany.

Asia-Pacific Dactylitis Treatment Market Insight

The Asia-Pacific Dactylitis Treatment market is expected to witness rapid growth, driven by improving healthcare access, rising awareness regarding autoimmune disorders, and expanding diagnostic capabilities across countries such as China, India, and Japan. Increasing prevalence of inflammatory musculoskeletal disorders, growing healthcare investments, and improving availability of biologic therapies are supporting regional market expansion. In addition, expanding specialty care infrastructure and rising focus on early diagnosis and chronic disease management are accelerating adoption of Dactylitis Treatment solutions across Asia-Pacific.

Japan Dactylitis Treatment Market Insight

The Japan Dactylitis Treatment market is witnessing consistent growth due to rising investments in autoimmune disease research, advanced healthcare technologies, and precision medicine initiatives. Healthcare providers and rheumatology specialists are increasingly adopting biologic therapies and targeted treatment approaches to improve long-term patient outcomes. Moreover, growing aging population, increasing prevalence of inflammatory arthritis conditions, and strong government support for advanced healthcare services are further contributing to market growth in Japan.

China Dactylitis Treatment Market Insight

The China Dactylitis Treatment market is growing rapidly, driven by expanding healthcare infrastructure, rising awareness regarding inflammatory disorders, and increasing access to advanced diagnostic and treatment services. Growing adoption of biologic therapies and supportive government healthcare reforms are significantly boosting market demand across hospitals and specialty clinics. In addition, rising investments in pharmaceutical innovation, improving patient access to rheumatology care, and increasing prevalence of autoimmune diseases are positioning China as one of the fastest-growing markets for Dactylitis Treatment globally.

Global Dactylitis Treatment Market Share

• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• UCB S.A. (Belgium)
• Bristol-Myers Squibb Company (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Sanofi S.A. (France)
• Merck & Co., Inc. (U.S.)
• AstraZeneca PLC (U.K.)
• GlaxoSmithKline plc (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Takeda Pharmaceutical Company Limited (Japan)
• Boehringer Ingelheim International GmbH (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Cipla Limited (India)
• Lupin Limited (India)
• Zydus Lifesciences Limited (India)
• Biocon Limited (India)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Celltrion Inc. (South Korea)
• Samsung Bioepis Co., Ltd. (South Korea)
• Sobi (Sweden)
• CSL Limited (Australia)
• Aurobindo Pharma Limited (India)

Latest Developments in Global Dactylitis Treatment Market

• In September 2024, UCB announced that the U.S. FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. The approval marked a major advancement in inflammatory disease management, as BIMZELX became the first dual IL-17A and IL-17F inhibitor approved for multiple chronic immune-mediated disorders, strengthening treatment options relevant to dactylitis-associated inflammatory conditions
• In April 2024, Teva Pharmaceuticals and Alvotech received U.S. FDA approval for Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara for the treatment of plaque psoriasis and psoriatic arthritis. The approval expanded access to cost-effective biologic therapies for autoimmune inflammatory disorders and supported broader availability of advanced treatment solutions associated with dactylitis management
• In October 2023, UCB received the first U.S. FDA approval for BIMZELX for adults with moderate-to-severe plaque psoriasis. The launch strengthened UCB’s immunology portfolio and laid the foundation for subsequent expansion into psoriatic arthritis and related inflammatory musculoskeletal conditions strongly associated with dactylitis treatment pathways
• In June 2025, Celltrion received FDA approval for a new pediatric formulation of ustekinumab biosimilar therapy for plaque psoriasis and psoriatic arthritis indications. The development highlighted the growing expansion of biosimilar-based autoimmune disease treatment options and increasing accessibility of biologic therapies across inflammatory arthritis care settings
• In January 2025, Biocon Biologics and its commercialization partner Yoshindo announced the launch of ustekinumab biosimilar injections in Japan following regulatory approval for psoriasis vulgaris and psoriatic arthritis treatment. The expansion strengthened biologic therapy penetration across Asia-Pacific and reflected increasing regional focus on affordable autoimmune disease management solutions relevant to dactylitis-associated inflammatory disorders
• In March 2026, Bristol Myers Squibb announced U.S. FDA approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis. The oral TYK2 inhibitor demonstrated significant improvements in joint and inflammatory symptom management during Phase III trials, representing an important advancement in targeted immunotherapy approaches for inflammatory musculoskeletal disorders linked with dactylitis progression

SKU-67568